Institut Català de la Salut
Hospital Universitari
Arnau de Vilanova

5PSQ-064

USE OF SORAFENIB IN CELLULAR HEPATOCARCINOMA IN ROUTINE CLINICAL PRACTICE

FJ Parada Saavedra[1], R Candeas Agustí[1],J.M. Miñana Calafat[2], C.L. Aracil Blanch[2], M. Gilabert Sotoca[1], JA Schoenenberger Arnaiz[1]

[1] Pharmacy Service, Hospital Universitari Arnau de Vilanova de Lleida
[2] Gastroenterology Service, Hospital Universitari Arnau de Vilanova de Lleida

❑ Objectives

• Describe the results of sorafenib treatment for hepatocelllular carcinoma (HCC) in terms of progression free survival (PFS), toxicity and compliance in clinical practice

❑ Methods

• Retrospective and descriptive
• Treated with sorafenib between January 2011 and May 2017
• Clinical and pharmacy dispensation electronic records
• Initial variables: age, gender, Child-Pugh status
• Follow-up variables: progression, death, worsening of clinical condition, unacceptable toxicity, lack of adherence, patient decision, loss of follow-up
• Median PFS and PFS at one year were obtained from SPSS® program applying Kaplan-Meier analysis

❑ Results

Follow-up 55 patients



Premature follow-up stopped (22)



Survival Analysis

Median PFS	CI 95%	PFS at one year
209±53 days	(105.2, 312.7)	19±8%



Follow-up patients >45 days (33)



Percentage of compliance (33)



❑ Discussion

• Sorafenib is a multikinase inhibitor approved for the treatment of HCC
• Clinical trials Sorafenib treatment resulted in a median overall survival of 9.2 months and a median time to progression of 5.5 months (SHARP study)
• Strengths points of our study were compliance evaluation and reasons of treatment discontinuation
• Lack of data on patients related outcomes

❑ Conclusion

• In more than one third of our HCC patients who started sorafenib, the drug could be deemed ineffective and harmful.
• In the patients who survived the initial phase of 45 days PFS yielded slightly better results than expected from clinical trials.

23rd Congress of eahp
HOSPITAL PHARMACISTS - SHOW US WHAT YOU CAN DO!
21st - 23rd March 2018 | Gothenburg, Sweden